🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

20 recruiting trials

for HR Positive/HER2 Low Breast Cancer

SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer NCT06340230Phase 21 site📍 Shenyang Shengjing Hospital · Tests: SHR-A1811 Injection + Adebrelimab Injection, SHR-A1811 Injection + Adebrelimab Injection, SHR-A1811 Injection A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer NCT07678957Phase 21 site📍 Beijing Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M07D1, DS-8201 Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study NCT06805812n/a24 sites📍 Aviano📍 Brescia📍 Catania Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Tests: Palbociclib, Ribociclib, Abemaciclib A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors NCT07383506Phase 112 sites📍 Scottsdale📍 Los Angeles📍 Palo Alto Cogent Biosciences, Inc. · Tests: CGT6297 To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer NCT06389006Phase 21 site📍 Shanghai RemeGen Co., Ltd. · Tests: Disitamab Vedotin for Injection, Toripalimab, Epirubicin, Cyclophosphamide Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer NCT04553770Phase 29 sites📍 Fullerton📍 Los Alamitos📍 Los Angeles Jonsson Comprehensive Cancer Center · Tests: Anastrozole, Therapeutic Conventional Surgery, Trastuzumab Deruxtecan A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC NCT06439771Phase 21 site📍 Shanghai MediLink Therapeutics (Suzhou) Co., Ltd. · Tests: YL202 should be intravenously infused A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer NCT07757230Phase 21 site📍 Guangzhou Shenyang Sunshine Pharmaceutical Co., LTD. · Tests: SSGJ-612 (HER2-targeted antibody), HER2-targeted ADC A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer NCT07497386Phase 21 site📍 Beijing Jiangsu HengRui Medicine Co., Ltd. · Tests: Trastuzumab Rezetecan for Injection, Trastuzumab Deruxtecan for Injection A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer NCT07701941Phase 1, Phase 272 sites📍 Los Angeles📍 Stanford📍 Aurora Daiichi Sankyo · Tests: Patritumab deruxtecan, Trastuzumab deruxtecan A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) NCT06966700Phase 3331 sites📍 Gilbert📍 Phoenix📍 Tucson Merck Sharp & Dohme LLC · Tests: Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel BEYOND Study: A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine Therapy NCT07597993n/a9 sites📍 Muscat📍 Doha📍 Mecca AstraZeneca · Tests: TDxd Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial) NCT05904964Phase 33 sites📍 Guangzhou📍 Shantou📍 Qionghai Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Tests: Disitamab vedotin, Endocrine therapy Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer NCT06207734Phase 213 sites📍 Berlin📍 Bremen📍 Dortmund Institut für Klinische Krebsforschung IKF GmbH at Krankenha… · Tests: Continuation of CDK4/6 inhibitor Palbociclib, Discontinuation of CDK4/6 inhibitor Palbociclib, Continuation of CDK4/6 i… Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08) NCT07383818Phase 25 sites📍 Harbin📍 Hefei📍 Shanghai First Affiliated Hospital of Zhejiang University · Tests: Neoadjuvant therapy combined with Trastuzumab Rezetecan and Toripalimab, Neoadjuvant Chemotherapy in Combination with T… Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment NCT07498478Phase 213 sites📍 Guangzhou📍 Wuhan📍 Changsha TransThera Sciences (Nanjing), Inc. · Tests: Tinengotinib at the optimal dose combined with Fulvestrant, Tinengotinib, tinengotinib combined with fulvestrant A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer NCT05911958Phase 21 site📍 Zhengzhou Henan Cancer Hospital · Tests: SHR-A1811 for injection PRE-ISPY Phase I/II Oncology Platform Program NCT05868226Phase 1, Phase 210 sites📍 Birmingham📍 Phoenix📍 Aurora QuantumLeap Healthcare Collaborative · Tests: ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Tucatinib, TTX-MC138 Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype NCT06486883Phase 279 sites📍 Graz📍 Linz📍 Vienna MedSIR · Tests: Trastuzumab deruxtecan (T-DXd, DS-8201a), CDK4/6i plus ET Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer NCT06837792Phase 21 site📍 Seoul Yonsei University · Tests: Experimental treatment arm, Control treatment arm
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy